Trial Profile
Phase IV, Multicenter, Open Label, Randomized Study of Rebif 44 mcg Administered Three Times Per Week by Subcutaneous Injection Compared With Copaxone 20 mg Administered Daily by Subcutaneous Injection in the Treatment of Relapsing Remitting Multiple Sclerosis
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 05 Dec 2018
Price :
$35
*
At a glance
- Drugs Interferon beta-1a (Primary) ; Glatiramer acetate
- Indications Multiple sclerosis
- Focus Therapeutic Use
- Acronyms REGARD
- Sponsors EMD Serono
- 25 Sep 2018 Results of pooled data from 17 clinical trials and post-marketing surveillance, were published in the Advances in Therapy.
- 27 Jun 2017 Results (n=917) assessing predictive value of modified Rio score using patient data from REFLEX(ION), REGARD, SPECTRIMS and PRISMS trials presented at the 3rd Congress of the European Academy of Neurology
- 11 Oct 2007 Results reported at ECTRIMS 2007 (1087283 and 1087295)